For people with mild cognitive impairment, most intervention studies enrolled people with MCI or Alzheimer's disease, with little evidence specific to related dementias. Multiple-etiology dementia means two or more brain pathologies occurring together with clinical dementia, and the National Academies says it may account for most dementia after age 65. The National Academies published its NIA-requested research priorities report in 2025 to guide NIH dementia investments, according to the report overview. The National Institute on Aging then carried that work into a 2026 dementia-care agenda focused on real-world diagnosis and treatment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does multiple etiologies mean with MCI?
- Who was studied?
- Who was not studied enough?
- What does this mean for treatment decisions?
- What can you do at your next visit?
- Frequently Asked Questions
What does multiple etiologies mean with MCI?
MCI means noticeable memory or thinking changes that do not prevent daily life. It is a risk state, not dementia itself, and the National Institute on Aging reports that an estimated 10-20 percent of people age 65 or older with MCI develop dementia over one year.
Many people with MCI stay stable or improve. That matters because mixed brain changes can already be present before dementia appears. A treatment aimed at one pathology may miss other active causes.
Who was studied?
Mostly people with MCI or Alzheimer's disease. The National Academies scoping review found that pattern across intervention studies, according to the review chapter.
That focus shapes what doctors can say with confidence. Findings apply best to early Alzheimer's with MCI or mild dementia. They transfer less well to people whose impairment comes mainly from other diseases.
Who was not studied enough?
People with Lewy body, frontotemporal, and vascular dementia had a paucity of specific intervention evidence in the review. People from groups most affected by dementia were also persistently underrepresented in observational studies and trials.
The National Academies points to aducanumab trials as an example, where participants were only 3.2 percent Hispanic or Latino and 0.6 percent African American. Results from narrow samples may not predict benefits or harms for other patients.
What does this mean for treatment decisions?
Current amyloid-targeted drugs offer only modest slowing of decline. The UW Medicine Memory and Brain Wellness Center states that lecanemab and donanemab were approved and tested only for early Alzheimer's with confirmed amyloid, meaning MCI or mild dementia, according to the center's treatment update.
They are not for moderate or advanced disease or for non-Alzheimer dementias. For mixed causes, NIA's 2026 agenda calls for building multiple etiologies into diagnosis and treatment choices, according to the 2026 summit report. It also calls for testing mixed-dementia markers in primary care and other real-world settings.
What can you do at your next visit?
Bring a list of memory changes, medicines, vascular risks, sleep problems, and family history. Ask whether testing has looked beyond Alzheimer's. The committee also notes its gap review relied on published systematic reviews, so a missing review may reflect delay or bias rather than proof of no studies.
- Ask what causes may be contributing, not only whether amyloid is present.
- Ask whether trial or clinic results fit your diagnosis, stage, age, and health conditions.
- Ask what follow-up will track change, safety, daily function, and caregiver needs.
- If a referral is offered, ask whether the clinic evaluates mixed causes and other dementias.
Frequently Asked Questions
Does MCI always turn into dementia?
No. Many people remain stable or improve, so doctors watch causes, health risks, and change over time before choosing treatment.
Why ask about mixed causes if memory drugs target amyloid?
More than one brain pathology can drive symptoms. Knowing the mix helps weigh likely benefit, safety, follow-up, and support needs.
You Might Also Like
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: Who Was Studied and Who Was Not for People With Mild Cognitive Impairment
- Midlife Monitoring Questions Raised by the AAIC 2026 Soccer Study: Who Was Studied and Who Was Not for People With Mild Cognitive Impairment
- Implementation-Ready Dementia Interventions in the 2026 NIA Report: Questions People With Mild Cognitive Impairment Can Ask About the Research
